BCM
CRSP icon

BluePath Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

BluePath Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-825
Closed -$37.4K – 152
2023
Q3 		$37.4K Buy
+825
New +$42.6K 0.03% 211

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BluePath Capital Management's CRSP Position: Q4 2023 in Review

BluePath Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 825 shares — an estimated $37.4K sold.

BluePath Capital Management first reported a position in CRSP in Q3 2023 and held it in 1 quarter. The position peaked at $37.4K in Q3 2023. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • BluePath Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 825 CRISPR Therapeutics shares in Q4 2023, an estimated $37.4K.
  • BluePath Capital Management first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's CRISPR Therapeutics position peaked at $37.4K in Q3 2023.
  • 472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.